3 citations
,
April 2023 in “Urology Herald” PRP shows promise in treating urological diseases but needs more research.
1 citations
,
April 2014 in “Journal of the Korean Society of Food Science and Nutrition” Unripe Rubus occidentalis extracts may help treat benign prostatic hyperplasia.
3 citations
,
December 2016 in “Der Urologe”
These medications for BPH have known risks and may have new side effects.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
These medications for BPH have known risks and may have new side effects.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
July 2004 in “Current Urology Reports”
11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
11 citations
,
December 2002 in “Controlled Clinical Trials” Simple methods using DHT levels effectively assess compliance.
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
December 2023 in “Bulletin of Pharmaceutical Sciences Assiut” Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.
3 citations
,
September 2013 in “Urology” More biopsy cores and MRI before biopsy can improve prostate cancer detection.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
March 2023 in “The Journal of Urology” Nocturia cases increased, but medication use declined, suggesting under-treatment.
12 citations
,
January 2018 in “Pharmacology & pharmacy” Pumpkin seed products may help improve prostate and bladder health by blocking certain enzymes and hormone receptors.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
18 citations
,
November 1994 in “Histochemical Journal” The enzyme PST is found in developing human kidneys and helps with detoxification and development.
153 citations
,
April 2009 in “Urology” Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
4 citations
,
October 2022 in “Current Urology” Platelet-rich plasma shows promise in reducing pain for bladder pain syndrome.
December 2008 in “The Journal of Urology” January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.